manilatimes30m
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...
ALS News Today1d
ALS Association tool aims to help patients navigate insurance issues
The ALS Association has launched a free tool to help ALS patients and their families navigate health insurance denials and ...
Medscape1d
ALS Trials Fail to Meet Key Endpoints…But It’s Still a Win and Here’s Why
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
emjreviews.com2d
HEALEY Trial: Pridopidine Fails to Slow ALS Progression
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
ALS News Today3d
Results published for first 4 drugs in HEALEY trial; 2 to be tested further
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
Daily4d
Verdiperstat use may not impact progression of amyotrophic lateral sclerosis: JAMA
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Platform trials streamline ALS therapy evaluation by rapidly ruling out ineffective drugs
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Four regimens fail endpoints simultaneously in HEALEY ALS trial
ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...